Related Experiment Video
Updated: Sep 12, 2025

Measurement of Cyclic Guanosine Monophosphate (cGMP) in Solid Tissues using Competitive Enzyme-Linked Immunosorbent Assay (ELISA)
Published on: July 3, 2025
[Mechanisms of hypertension inducing erectile dysfunction via the cGMP/PKG signaling pathway: An investigation using
Jun-Long Feng1, Hai-Song Li1, Song Sun2
1Department of Andrology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100700, China.
Objective:
To explore the mechanism of hypertension inducing erectile dysfunction (ED) using transcriptomics and network pharmacology.
Methods:
We randomly divided 12 male rats with spontaneous hypertension (SHT) into an L-arginine (LA) group (n = 6) and an SHT model control (MC) group (n = 6), took another 6 Wistar Kyoto male rats as normal controls (NC), and treated the animals in the LA group by intraperitoneal injection of LA at 400 mg/kg and those in the latter two groups with physiological saline, once a day, all for 7 days. Then we observed the blood pressure and penile erection of the rats, and determined the expressions of the cGMP/PKG signaling pathway-related proteins and mRNAs in different groups using ELISA, Western blot and RT-qPCR.
Results:
Transcriptomics combined with network pharmacology showed that the cGMP/PKG signaling pathway played a key role in hypertension-induced ED. In vivo animal experiments revealed a significantly lower frequency of penile erections in the MC than in the NC group (1.33 ± 0.52 vs 2.67 ± 0.51, P<0.05). The protein expressions of eNOS, PKG and sGC were markedly decreased in the model controls compared with those the normal controls (P<0.05), but remarkably upregulated in the LA group compared with those in the MC group (P<0.05).
Conclusion:
Hypertension decreases the expressions of eNOS, NO, sGC, cGMP and PKG proteins and the level of testosterone by inhibiting the cGMP/PKG signaling pathway, which consequently suppresses the relaxation of the penile vascular smooth muscle and reduces erectile function.
Related Concept Videos
Nitric Oxide Signaling Pathway
Hypertension II: Pathophysiology
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Antihypertensive Drugs: Vasodilators
Hypertension and Regulation of Blood Pressure
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:

